Nerandomilast slowed FVC decline in US IPF patients compared to placebo, with a favorable safety profile and tolerability. The FIBRONEER-IPF trial was a double-blind, placebo-controlled study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results